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Abstract
Objective: Endogenous hypercortisolism is a chronic condition associated with severe metabolic disturbances and 
cardiovascular sequela. The aim of this study was to characterize metabolic alterations in patients with different 
degrees of hypercortisolism by mass-spectrometry-based targeted plasma metabolomic profiling and correlate the 
metabolomic profile with clinical and hormonal data.
Design: Cross-sectional study.
Methods: Subjects (n = 149) were classified according to clinical and hormonal characteristics: Cushing’s syndrome 
(n = 46), adrenocortical adenomas with autonomous cortisol secretion (n = 31) or without hypercortisolism (n = 27). 
Subjects with suspicion of hypercortisolism, but normal hormonal/imaging testing, served as controls (n = 42). Clinical 
and hormonal data were retrieved for all patients and targeted metabolomic profiling was performed.
Results: Patients with hypercortisolism showed lower levels of short-/medium-chain acylcarnitines and branched-
chain and aromatic amino acids, but higher polyamines levels, in comparison to controls. These alterations were 
confirmed after excluding diabetic patients. Regression models showed significant correlation between cortisol 
after dexamethasone suppression test (DST) and 31 metabolites, independently of confounding/contributing factors. 
Among those, histidine and spermidine were also significantly associated with catabolic signs and symptoms of 
hypercortisolism. According to an discriminant analysis, the panel of metabolites was able to correctly classify subjects 
into the main diagnostic categories and to distinguish between subjects with/without altered post-DST cortisol and 
with/without diabetes in >80% of the cases.
Conclusions: Metabolomic profiling revealed alterations of intermediate metabolism independently associated with 
the severity of hypercortisolism, consistent with disturbed protein synthesis/catabolism and incomplete β-oxidation, 
providing evidence for the occurrence of metabolic inflexibility in hypercortisolism.
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Introduction
Glucocorticoids – with cortisol as the main endogenous 
hormone in humans – are among the most powerful 
metabolic regulators and most widely used anti-inflam-
matory drugs. They induce a plethora of physiological 
effects on a variety of target tissues, stimulating hepatic 
gluconeogenesis, inhibiting glucose uptake in adipose and 
muscle tissue and enhancing lipolysis (1). According to its 
central role in physiology, disturbances in glucocorticoid 
secretion or prolonged glucocorticoid therapy have 
unwarranted clinical consequences. In fact, endogenous 
hypercortisolism also referred to as Cushing’s syndrome 
(CS) is associated with increased mortality (2), due to 
impaired glucose metabolism, infectious and thrombotic 
complications, and musculoskeletal and cardiovascular 
co-morbidities (3). Even in patients with milder forms of 
hypercortisolism, who are not clinically evident as overt 
CS, metabolic and cardiovascular complications are well 
recognized (4, 5, 6).
The diagnosis of CS is dependent on a combination 
of clinical and biochemical tests whose interpretation 
can be misleading and requires expert knowledge (7). 
The identification of metabolic alterations potentially 
related to the level of cortisol excess in patients with 
hypercortisolism, may aid in disease detection and 
classification of its severity. Moreover, the characterization 
of the metabolic profile of hypercortisolism may represent 
a useful basis to tailor targeted treatments of diseases 
associated with excessive exposure to glucocorticoids, in 
endogenous and iatrogenic CS, the latter being the most 
common form of hypercortisolism.
Mass spectrometry (MS)-based assays have recently 
revolutionized the analysis of small molecules in 
biological fluids, thanks to their high accuracy and 
sensitivity, and have been successfully employed for 
steroid profiling in patients with hypercortisolism (8, 9). 
The aim of our study was to characterize the profile of 
a wide panel of metabolites in plasma of patients with 
different degrees of endogenous glucocorticoid excess 
by tandem mass spectrometry (MS/MS) and to identify 
potential relationships with clinical phenotypes.
Subjects and methods
Subjects
We enrolled 104 consecutive patients evaluated in three 
German tertiary clinical centers. These were classified 
according to clinical characteristics and the results of 
1-mg dexamethasone suppression test (DST) into three 
groups. The first group consisted of patients with CS 
(n = 49), diagnosed according to current guidelines (7) 
and included 27 with ACTH-dependent CS. Among 
them, three patients had ectopic CS. The remaining two 
groups consisted of patients with incidentally discovered 
benign adrenocortical tumors, who had no typical signs/
symptoms of CS and either post-DST cortisol ≤50 nmol/L 
(1.8 µg/dL) (non-secreting – NS, n = 27) or >50 nmol/L 
(autonomous cortisol secretion – ACS, n = 31), according 
to the current European guidelines (10). Controls were 
selected among individuals consecutively evaluated for 
an initial clinical suspicion of hypercortisolism (mainly 
because of weight gain or hypertension), in whom cortisol 
hypersecretion was ruled out by appropriate hormonal 
testing (n = 42). All subjects gave written informed consent 
for the analysis. The ethics committee of each individual 
institution approved the study.
Clinical and hormonal evaluation
Clinical and hormonal data of patients were drawn 
from the German Cushing’s registry (CUSTODES) 
and the European Network for the Study of Adrenal 
Tumors (ENSAT) database. Plasma cortisol, ACTH and 
midnight salivary cortisol were measured as described 
previously (11). Post-DST cortisol was measured during 
the morning, 8–10 h after oral administration of 1-mg of 
dexamethasone, and levels <50 nmol/L were considered 
adequately suppressed.
Sample preparation and metabolomic profiling
Plasma was extracted from blood samples obtained 
after overnight fasting, following standard operating 
procedures. After centrifugation at room temperature for 
10 min at 2750 g, samples were transferred into pre-cooled 
collection tubes, vortexed, aliquoted on ice, immediately 
frozen in liquid nitrogen and stored at −80°C until assayed.
Targeted metabolite quantification was performed 
using the AbsoluteIDQ-p180 Kit (BIOCRATES AG, Austria). 
Details on assay methods have been previously described 
(12). Briefly, targeted metabolite consists of a HPLC 
separation step (LC) and a flow injection analysis step 
(FIA), followed by MS analyses (LC–MS/MS and FIA-MS/
MS respectively). The LC–MS/MS procedure enables 
quantification of 21 amino acids and 21 biogenic amines. 
The FIA-MS/MS procedure quantifies 146 additional 
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metabolites, covering free carnitine, 39 acylcarnitines, 38 
diacyl- (PC aa), 38 acyl/alkyl- (PC ae) and 14 lyso- (lyso 
PC) phosphatidylcholines, 15 sphingomyelins (SM) and 
sum of hexoses. Limits of detection were set to three 
times the concentration values of the zero samples (PBS). 
Internal standards served as reference for calculation 
of metabolite concentrations given in µM. For quality 
control and normalization, five samples of the same 
human reference plasma have been measured with each 
batch of measurement. Quality control of metabolomic 
dataset was performed as previously described (12).
Statistical analysis
Data are presented as mean ± s.d., if not otherwise 
specified, or frequencies. Data normalization was 
performed by dividing each metabolite concentration by 
the mean of the concentration of reference plasma of the 
respective plate, to reduce inter-assay variability. In case 
of non-normal distribution, logarithmic transformation 
was performed. Continuous variables’ differences among 
groups were tested with one-way ANOVA. ANCOVA was 
performed to adjust for the effect of age in continuous 
variables’ comparison among groups. Selected inter-
group differences were analyzed by simple contrasts. 
Chi-square test was performed for analysis of categorical 
variables. The Benjamini–Hochberg procedure was 
applied to control the false discovery rate (FDR) at 
α level 0.1. Discriminant analysis was performed to 
assess the predictive scores for classification of patients 
into the different diagnostic categories and into four 
newly defined groups, based on the presence/absence 
of diabetes, and post-DST cortisol levels below/above 
50 nmol/L. A ROC curve was built to test the sensitivity 
and the specificity of a predictive score obtained by 
the analysis of coefficients of the most discriminant 
metabolites. Regression models were built to assess 
the relationship between each metabolite with post-
DST cortisol, including age, body mass index (BMI), 
diabetes and dyslipidemia. The relationship between 
a selected panel of metabolites and catabolic signs 
of hypercortisolism was investigated by multinomial 
logistic regression, including age and diabetes into the 
model. Statistical analysis was performed with SPSS, 
version 23 (IBM). 3D scatterplots were prepared using 
JMP (SAS).
Results
General cohort description
General and hormonal characteristics of included patients 
are provided in Table  1. Age was significantly different 
among groups, whereas BMI and sex distribution were 
comparable. Hypertension and dyslipidemia were more 
frequent in patients with hypercortisolism. The prevalence 
Table 1 General characteristics, clinical and hormonal data of controls and patients with non-secreting adenomas, autonomous 
cortisol secretion and Cushing’s syndrome. Data are expressed as mean with range in parenthesis or frequencies.
    Cushing’s syndrome  
 Controls 
Non-secreting 
adenomas 
Autonomous 
cortisol secretion ACTH-independent ACTH-dependent P value 
Patients, n 42 27 31 22 27  
General characteristics
Females, n (%) 31 (73.8) 19 (70.4) 19 (61.3) 16 (72.7) 19 (70.4) 0.830
Age (years) 38.2 (16.0–62.9) 56.8 (31.5–77.0) 63.9 (40.5–87.2) 51.3 (21.0–72.3) 48.2 (16.8–77.8) <0.001*
BMI (kg/m2) 32.7 (17.9–51.3) 31.3 (19.0–45.2) 28.3 (18.4–38.9) 30.4 (20.8–49.7) 28.1 (19.8–46.8) 0.108
Clinical data, n (%)
Hypertension 23/39 (59.0) 15/27 (55.6) 27/31 (87.1) 17/21 (80.0) 22/27 (81.5) 0.015
Type 2 diabetes 6/41 (14.6) 7/27 (25.9) 9/31 (29.0) 6/21 (28.6) 9/26 (34.6) 0.405
Dyslipidemia 5/31 (16.1) 9/27 (33.3) 11/30 (36.7) 8/21 (38.1) 15/25 (60.0) 0.020
Previous CVD 3/42 (7.1) 4/27 (14.8) 7/31 (22.6) 2/21 (9.5) 4/27 (14.8) 0.406
Hormonal data
DST (nmol/L) 30.4 (13.8–50.0) 35.9 (19.3–50.0) 129.4 (52.4–744.9) 326.7 (74.5–761.5) 593.2 (102.0–1914.7) <0.001
ACTH (pmol/L) 2.9 (1.1–6.2) 2.9 (1.3–5.1) 1.8 (0.7–4.8) 1.3 (1.1–3.3) 18.1 (3.8–86.2) <0.001
LNSC (nmol/L) 0.3 (0.1–0.8) 1.5 (0.1–4.4) 1.3 (0.1–7.7) 4.0 (0.5–16.0) 2.9 (0.6–8.7) <0.001
Hormonal data are expressed in System International (SI) units. To convert cortisol from the SI units (nmol/L) to the metric units (µg/dL), divide by the 
conversion factor 27.59. To convert ACTH from the SI units (pmol/L) to the metric units (pg/mL), divide by the conversion factor 0.22.
*All simple contrasts are significant at P < 0.05, except non-secreting adenomas vs ACTH-independent Cushing’s syndrome (P = 0.15) and  
ACTH-independent vs ACTH-dependent Cushing’s syndrome (P = 0.41).
BMI, body mass index; DST, 1-mg dexamethasone suppression test; LNSC, late-night salivary cortisol.
AUTHOR COPY ONLY
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
177:2 230Clinical Study G Di Dalmazi and others Metabolic alterations in 
Cushing’s syndrome
www.eje-online.org
of diabetes was not significantly different among groups. 
Hormonal values were different by definition.
Metabolomic profiles in patients with 
hypercortisolism
The results of the metabolomics profiling are detailed in 
Supplementary Table 1 (see section on supplementary data 
given at the end of this article). Patients with CS proofed 
to have lower levels of several amino acids and increased 
levels of spermidine and taurine, when compared to 
controls. PC aa C38:3, PC aa C40:4 and PC ae C36:4 
were significantly lower than those in controls. Several 
alterations observed in CS were also present in patients 
with ACS, i.e. lower levels of histidine, tryptophan, valine 
and PC aa C38:3 and PC aa C40:4, and increased levels of 
taurine, in comparison to controls. The comparison of the 
two subtypes of CS did not highlight relevant differences, 
apart from increased levels of spermine and taurine, and 
lower levels of PC ae C36:4, in ACTH-independent CS.
Considering the significant difference in age among 
the groups, comparison of the metabolite panel was 
performed after adjustment for age. Following this 
adjustment (Supplementary Table  2), patients with 
CS had significantly lower plasma levels of carnitine, 
acetyl-carnitine and several acylcarnitines up to C14, 
when compared to controls. Amino acids, including 
branched-chain (BCAA) and aromatic amino acids 
(AAA), and PC aa C38:3, PC aa C38:4 and PC aa C40:4 
were significantly lower in plasma of patients with CS, 
whereas spermidine showed higher values, with respect 
to controls. The alterations in plasma levels of carnitine, 
acylcarnitines and phosphatidylcholines were also 
confirmed in patients with ACS. No difference in plasma 
levels of sphingomyelins or hexoses was found among 
groups. The subgroup analysis of the metabolomics 
profiles between patients with ACTH-independent CS 
and ACS revealed that only spermidine was significantly 
higher in the former group (P = 0.014).
Relationship between metabolomic profiles and 
clinical, hormonal and metabolic characteristics
To test whether the presence of diabetes and 
dyslipidemia could represent a potential confounder 
in the interpretation of the results, differences among 
groups were further analyzed in patients without those 
co-morbidities. Difference in post-DST and midnight 
cortisol were firstly analyzed between patients with 
and without co-morbidities separately in each group, 
to check whether the hormonal profile could be more 
severe in the former, generating potential bias in the 
results. However, no such differences in hormonal 
values were detectable between patients with diabetes 
(+/− dyslipidemia) and those without (data not shown). 
General characteristics and metabolomic profiling of non-
diabetic patients (n = 109) are reported in Supplementary 
Table  3. After adjustment for age, acetyl-carnitine and 
hydroxytetradecadienylcarnitine were lower in patients 
with hypercortisolism (ACS and CS) than in controls, 
alongside with BCAA, histidine, tyrosine, kynurenine 
and PC aa C38:3, PC aa C38:4 and PC aa C40:4. 
Spermidine levels remained higher in plasma of patients 
with CS than those in controls. Notably, free carnitine, 
dodecenoylcarnitine and several C14 acylcarnitines were 
significantly lower in patients with hypercortisolism, 
when compared to controls, even though at FDR 
α > 0.1. The alterations of ten of those metabolites were 
also observed in subjects with neither diabetes nor 
dyslipidemia (n = 70), i.e. acetyl-carnitine (P = 0.004), 
hydrohytetradecadien-carnitine (P = 0.001), isoleucine 
(P = 0.016), leucine (P = 0.014), valine (P = 0.010), tyrosine 
(P = 0.007), kynurenine (P = 0.002), spermidine (P < 0.001), 
PC aa C38:3 (P = 0.009) and PC aa C40:4 (P = 0.012) (data 
not shown).
Taking into account the association between 
metabolites and the different categories of cortisol 
hypersecretion, a regression model was built to 
investigate the relationship with post-DST cortisol, 
including potential contributing/confounding factors 
(Table  2). Post-DST cortisol levels were significantly 
associated with 31 metabolites, irrespective of age, BMI 
and presence of diabetes and/or dyslipidemia. Notably, 
several long-chain acylcarnitines >C16 and polyamines 
were positively associated, whereas amino acids and most 
phosphatidylcholines ≥C38 were negatively associated 
with post-DST cortisol. A multinomial logistic regression 
model was assessed to analyze the relationship between 
those metabolites and the presence of typical catabolic 
signs/symptoms of hypercortisolism (myopathy, thin 
skin, and easy bruising). Overall, histidine was negatively 
associated with the presence of catabolic signs of CS (odds 
ratio (OR) 0.02, 95% CI 0.002–0.27; P = 0.003), whereas 
spermidine was positively associated (OR 1.93, 95% CI 
1.19–3.13; P = 0.007).
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Considering the alterations in acylcarnitines and 
polyamines, we investigated the relationship between 
post-DST cortisol and metabolite ratios indicative of 
activity of carnitine-palmitoyl-transferase 1 (CPT-1) 
and enzymes of the polyamine biosynthetic pathway 
(arginase, ornithine decarboxylase (ODC), spermidine and 
spermine synthase). CPT-1, arginase and ODC activities 
were positively associated with post-DST cortisol, whereas 
a negative association was found for spermine synthase, 
independently of confounding factors (Table  2). No 
significant association was recorded for spermidine 
synthase (P = 0.054).
The analyses performed after exclusion of the three 
patients with ectopic CS did not change the results (data 
not shown).
Discriminant analysis for diagnosis and differential 
diagnosis of CS
Based on a discriminant analysis taking into account 
the metabolomic panel as well as age, 88.7% of the 
patients could be correctly classified into the four main 
diagnostic groups, i.e. CS, ACS, NS and controls (Fig. 1A). 
The most discriminant metabolites for identification of 
A Predicted group membership Sensitivity 
(%)
Specificity 
(%) PPV (%)
NPV 
(%)Controls NS ACS CS
Controls (n=41) 37 (90.2) 1 (2.4) 1 (2.4) 2 (4.9) 90.2 98.0 94.9 96.1
NS (n=25) 2 (8.0) 20 (80.0) 2 (8.0) 1 (4.0) 80.0 95.7 80.0 95.7
ACS (n=30) 0 (0.0) 4 (13.3) 24 (80.0) 2 (6.7) 80.0 96.4 85.7 94.7
CS (n=45) 0 (0.0) 0 (0.0) 1 (2.2) 44 (97.8) 97.8 94.8 89.8 98.9
Predicted group membership Predicted group membership
ACS AI CS AD CS AI CS + ACS AD CS
ACS (n=31) 26 (83.9) 4 (12.9) 1 (3.2) AI CS + ACS (n=53) 48 (90.6) 5 (9.4)
AI CS (n=22) 6 (27.3) 15 (68.2) 1 (4.5) AD CS (n=27) 7 (25.9) 20 (74.1)
AD CS (n=27) 1 (3.7) 3 (11.1) 23 (85.2)
B Predicted group membership
No hypercortisolism
No diabetes
No hypercortisolism
Diabetes
Hypercortisolism
No diabetes
Hypercortisolism
Diabetes
No hypercortisolism
No diabetes (n=53) 45 (84.9) 0 (0.0) 8 (15.1) 0 (0.0)
No hypercortisolism
Diabetes (n=12) 3 (25.0) 8 (66.7) 1 (8.3) 0 (0.0)
Hypercortisolism
No diabetes (n=50) 5 (10.0) 1 (2.0) 42 (84.0) 2 (4.0)
Hypercortisolism
Diabetes (n=23) 0 (0.0) 0 (0.0) 6 (26.1) 17 (73.9)
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
No hypercortisolism
No diabetes 84.9 90.6 84.9 90.6
No hypercortisolism
Diabetes 66.7 99.2 88.9 96.9
Hypercortisolism
No diabetes 84.0 83.0 73.7 90.1
Hypercortisolism
Diabetes 73.9 98.3 89.5 95.0
Figure 1
3D scatter plots of the scores obtained by the discriminant analysis. (A) Discriminant scores for classification of controls, NS, ACS 
and CS, showing that overall 88.7% of patients were correctly classified. The discriminant analysis also showed a good overall 
correct classification rate into ACS, AI CS and AD CS (80.0%) and when patients with adrenal hypercortisolism (AI CS + ACS) and 
AD CS were considered (85.0%). (B) The figure shows the scores obtained by the discriminant analysis for grouping of four novel 
identified groups, based on the levels of cortisol after DST (normal vs altered) and presence/absence of diabetes. The three scores 
were able to correctly classify 81.2% of the patients overall. No overlap was observed between diabetic patients with and 
without alterations of post-DST cortisol, indicating that the metabolic fingerprint of diabetes may be different according to the 
concomitant presence of hypercortisolism. Data in tables are expressed as numbers with percentages in parentheses. 
ACS, autonomous cortisol secretion; AD CS, ACTH-dependent CS; AI CS, ACTH-independent CS; CS, Cushing’s syndrome; DST, 
1-mg dexamethasone suppression test; NPV, negative predictive value; NS, non-secreting adrenocortical adenomas; PPV, positive 
predictive value.
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patients with CS were spermidine, kynurenine, isoleucine 
and PC aa C40:4. The predictive score calculated by 
the discriminant coefficient for all those metabolites 
showed a sensitivity of 77.6% and a specificity of 72.0% 
in identifying CS (area under the curve – AUC 0.808, 
95% CI 0.734–0.883, P value <0.001). A plot of the ROC 
curve is shown in Supplementary Fig. 1. Considering the 
differential diagnosis of endogenous hypercortisolism into 
ACS, ACTH-independent and ACTH-dependent forms, 
metabolomic profiling provided an overall classification 
rate of 80.0%, when restricting the analysis to those cases, 
and 85.0%, when patients with adrenal hypercortisolism 
(ACS + ACTH-independent) and ACTH-dependent CS were 
included (Fig.  1A). Finally, the analysis was performed 
to investigate the discriminant power of metabolites 
for subjects with or without hypercortisolism (post-DST 
cortisol below or above 50 nmol/L) and with or without 
diabetes respectively. According to this discrimination, 
81.2% of the patients were correctly classified (Fig. 1B).
Discussion
The present study focused on the quantification of a 
large panel of metabolites in plasma of patients with 
hypercortisolism, which was performed for the first time 
by using a highly accurate MS-based assay. The results 
of our study clearly indicate that the metabolic profile 
of patients with hypercortisolism is disturbed involving 
metabolism of amino acids and polyamines, as well as 
fatty acid β-oxidation (FAO). Most metabolic alterations 
were also associated with the severity of cortisol excess, 
as well as with clinical signs and symptoms of steroid-
induced catabolism.
Making usage of the full spectrum of analytes, we 
assessed the discriminating power of the assay as an aid 
for patient classification based on a single blood sample 
drawn in the morning. By using metabolites and age, 
>80% of patients could be classified between those with 
CS, ACS, NS and those in whom hypercortisolism had 
been excluded. Similarly, the profiles could be utilized 
to separate between ACTH-dependent and independent 
hypercortisolism in up to 85% of cases. Finally, the 
metabolomic profile was able to discriminate metabolites 
mainly associated with cortisol hypersecretion from those 
related to type-2 diabetes, even though with some overlap 
between groups. In contrast, no overlap was observed 
within the group of diabetic patients with and without 
alterations of post-DST cortisol, indicating that the 
metabolic fingerprint of diabetes differs according to the 
concomitant presence of hypercortisolism.
Age-adjusted analysis revealed alterations in amino 
acids and polyamines in patients with hypercortisolism, 
which were well correlated with post-DST cortisol levels. 
The reduction of BCAA (isoleucine, leucine and valine) was 
among the most frequently observed characteristics. BCAA 
are known to be increased proportionally to the muscle 
mass in non-fed states, to provide substrates for energy 
production, and to be reduced in severe muscle atrophy 
(13). Their lower levels in patients with hypercortisolism 
may uncover a significant reduction of muscular mass, a 
well-known consequence of hypercortisolism and one of 
the most specific clinical characteristics of patients with 
endogenous and iatrogenic CS (3). BCAA reduction in 
hypercortisolism was even more marked after removing 
the confounding effect of diabetes, which is associated 
with disruption of amino acid metabolism and proximal 
muscle atrophy (14). Interestingly, studies on animal 
models highlighted a role for BCAA in reversing 
dexamethasone-induced muscle atrophy, shedding light 
on the interplay between glucocorticoid and BCAA in 
maintaining CS-related sarcopenia (15). Several AAA were 
also decreased during hypercortisolism. Histidine plays 
major roles as a component of collagen and as a precursor 
of histidine-containing dipeptide beta-alanyl-l-histidine 
(carnosine) in human skeletal muscle (16). In our cohort, 
histidine was inversely associated with the severity of 
hypercortisolism and showed a negative correlation with 
clinically relevant signs and symptoms such as proximal 
muscle weakness, skin thinning and easy bruising. These 
findings support the hypothesis that histidine might 
represent a marker and a potential mediator of cortisol-
related alterations of collagen and skeletal muscle. 
Disruption of tryptophan metabolism may also contribute 
to steroid-dependent skeletal muscle alteration. Given 
that tryptophan and its metabolite kynurenine have 
shown positive effects on the expression of myogenic 
markers in animal models (17), reduced levels of those 
compounds may represent a pejorative factor contributing 
to cortisol-induced reduction of protein synthesis. Due 
to its ability to cross the blood–brain barrier (18), lower 
plasma tryptophan levels may also be associated with a 
reduced intracerebral serotonin production. Whether this 
alteration could contribute to CS-related depression is an 
intriguing hypothesis that deserves further studies.
Polyamines are low-molecular-weight, positively 
charged compounds acting as mediators of several 
biological processes, mainly cell growth, response to 
oxidative stress (19) and cortisol-induced inflammatory 
response (20). Polyamines are produced by de novo 
synthesis from proline, glutamine and arginine, with 
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ornithine decarboxylase (ODC) as the rate-limiting step. 
Spermidine levels were significantly increased in patients 
with CS and polyamines correlated with the severity 
of hypercortisolism. Furthermore, spermidine was 
clearly associated with catabolic signs and symptoms of 
hypercortisolism. Increased polyamine production could 
rely on the direct activation of ODC by cortisol, given 
that the ODC promoter contains hormonally regulated 
transcription factor response elements (21) and based on 
animal studies demonstrating that ODC is activated by 
dexamethasone (22). In our cohort, indirect measures of 
ODC and arginase activity were positively associated with 
post-DST cortisol levels, indicating arginine as a potential 
source for ornithine generation in hypercortisolism and a 
cortisol-related ODC activation. Conversely, the inverse 
association with spermidine/spermine ratio may represent 
either an overload of the non-inducible spermine synthase 
or an increased catabolism of spermine through N-acetyl-
spermine. The role of polyamines in human diseases has 
recently been claimed in several studies, showing that their 
production was increased in models of experimentally 
induced cardiac hypertrophy (23) and that spermidine 
had detrimental effects on cardiomyocytes under hypoxic 
stress (24). Accordingly, polyamines were also found 
increased in patients with heart failure (25). Considering 
these results and previous studies demonstrating interplay 
between cortisol and polyamines during inflammatory 
processes (20), the novel finding on perturbation of 
polyamine metabolism in hypercortisolism is interesting. 
The effects of their elevation on the cardiovascular system 
and on inflammation should be further clarified in 
targeted studies.
Alterations in carnitine and acylcarnitines 
point toward disturbances of FAO in patients with 
hypercortisolism, as also shown in previous studies (26). 
During fed-to-fast transition, the switch from glucose 
to fatty acid metabolism leads to increased uptake of 
carnitine and long-chain fatty acids, which are combined 
by CPT1 to generate acylcarnitines and internalized in 
the mitochondrial matrix through the carnitine shuttle, 
initiating FAO and producing acetyl-CoA to sustain the 
Krebs cycle. When excessive, acetyl-CoA is converted 
to the membrane-permeable acetyl-carnitine by the 
carnitine acetyltransferase (CRAT) and exported. The 
reduced levels of acylcarnitines up to C14 and the relative 
increase of >C16 acylcarnitines, associated with post-
DST cortisol levels, point toward an incomplete FAO in 
patients with hypercortisolism. The increased availability 
of free fatty acids due to cortisol-induced lipolysis (3) 
may represent the trigger for the metabolic overload 
to mitochondria and depletion of components of the 
Krebs cycle, similar to the cascade of events postulated 
as a causative mechanism in type-2 diabetes (27). The 
low levels of plasma acetyl-carnitine in hypercortisolism 
provide additional clues. Considering that intra-matrix 
accumulation of long-chain acyl-CoA is an inhibitory 
signal for CRAT (28), it is conceivable that the sustained 
cortisol-driven metabolic overload may lower CRAT 
activity. Therefore, the reduced acetyl-carnitine levels may 
uncover an increase in intra-matrix FAO-derived acetyl-
CoA, which, in turn, inhibits pyruvate dehydrogenase 
and glycolytic processes (29). Additionally, in vitro studies 
have demonstrated inhibitory effects of glucocorticoids 
on enzymes of FAO (long-, medium- and short-chain 
acyl-CoA dehydrogenases), without affecting the activity 
of very-long-chain acyl-CoA dehydrogenases (30). These 
results give feed to the hypothesis that the incomplete 
FAO in patients with hypercortisolism may rely on a 
selective inhibition at C14 fatty acyl-CoA, due to direct 
cortisol-dependent effects.
Interestingly, no alteration of SM levels was identified 
among groups in all comparisons. This result may indicate 
that composition of plasma membrane as well as activities 
of enzymes of the SM cycle and ceramide levels may not 
be affected by hypercortisolism. However, further targeted 
studies are required to unravel this complex aspect.
We could not analyze the potential effects of 
androgens on the different metabolomic profiles in 
patients with ACTH-dependent vs ACTH-independent 
CS because of the lack of a sufficient number of data 
to perform a reliable statistical analysis. This intriguing 
aspect should be investigated in targeted future studies.
A summary of the main metabolic alterations in 
patients with hypercortisolism is illustrated in Fig.  2. 
Levels of amino acids and polyamines are consistent with 
prolonged muscular catabolism and inhibition of protein 
synthesis in the context of sustained hypercortisolism. 
Interestingly, several alterations were replicated in patients 
with ACS, leading to the intriguing hypothesis that some 
degrees of protein catabolism and muscular atrophy could 
be relevant also in patients without classical clinical signs 
of CS. Moreover, the metabolic profiling of acylcarnitines 
provides indirect evidences that the metabolic inflexibility 
(the impossibility to switch from fatty acid to glucose 
oxidation and vice versa) (31), described in patients 
with type-2 diabetes, may be a characteristic feature 
of hypercortisolism.
Beside the potential mechanisms underlying the 
differences among groups, which should be considered 
speculative, mainly due to the cross-sectional design, this 
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Figure 2
Summary of the most important plasma metabolomic profile alterations identified in association with hypercortisolism and 
speculative hypothesis on the main pathogenetic pathways involved. Black arrows indicate known pathways altered by 
hypercortisolism, whereas gray arrows point at potential novel pathways. In the left box (summarizing the altered steps of fatty 
acid β-oxidation) and in the cartoon of the urea cycle, pathways activated by hypercortisolism are highlighted in red, whereas 
downregulated pathways are shown in light blue. Dotted lines indicate potential novel pathways. Metabolites listed in the blood 
vessel are marked in blue and yellow according to their levels in plasma (reduced vs increased respectively). ARG, arginase; 
BCAA, branched chained amino acids; CACT, carnitine–acylcarnitine translocase; CM, cell membrane; CPT, carnitine-palmitoyl-
transferase; CRAT, carnitine acetyl-CoA transferase; FAT, fatty acid transporter; FFA, free fatty acids; His, histidine; IMM, inner 
mitochondrial membrane; Kyn, kynurenine; LC AC, long-chain acylcarnitines; LC ACoA, long-chain acyl-CoA; LC-DH, long-chain 
acyl-CoA dehydrogenase; LC FA, long-chain fatty acids; MC-DH, medium-chain acyl-CoA dehydrogenase; ODC, ornithine 
decarboxylase; OMM, outer mitochondrial membrane; PDH, pyruvate dehydrogenase; SC-DH, short-chain acyl-CoA 
dehydrogenase; S/MC FA, short/medium-chain fatty acids; SpdS, spermidine synthase; SpmS, spermine synthase; 
TCA cycle, tricarboxylic acid cycle; Trp, tryptophan; VLC-DH, very long-chain acyl-CoA dehydrogenase.
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study provides information about several specific markers 
that can be identified in patients with hypercortisolism. 
Therefore, the results of this study should be interpreted 
in the light of a basis for future research investigating a 
more targeted panel of metabolites in a larger population, 
in a prospective setting. Moreover, the results obtained 
in this unique model of hypercortisolism provide an 
invaluable basis to unravel the metabolic correlates of 
patients under chronic glucocorticoid treatment, which 
are often difficult to be interpreted due to interferences 
by the underlying glucocorticoid-requiring pathological 
condition. Additionally, the possibility to use a restricted 
panel of metabolites for identifying patients with cortisol-
related metabolic alterations may have a high impact 
on the classification of ACS, which still relies on a non-
standardized combination of hormonal tests.
Future studies are needed to prospectively assess 
the relationship between metabolic alterations and 
co-morbidities progression, especially in ACS, and the 
utility of nutritional support (e.g. carnitine and targeted 
amino acids supplementation) in patients with 
persistent/recurrent CS and those under chronic 
glucocorticoid treatment.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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